Overzicht
Wijziging aandelenprijs
24u
Huidig
Min
48.76
Max
48.76
Aanbevelingen | Buy |
|---|---|
12 Maanden Prognose | +35.05% upside |
Volgende Winsten | 3 nov 2026 |
|---|
Nieuwssentiment
By Acuity
16%
84%
15 / 339 Rangschikking in Healthcare
Rigel Pharmaceuticals Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
23 sep 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares fell sharply amid a declining broader market, reaching a low of nearly 3.75% below Tuesday's close before a slight recovery.
Lezen
18 sep 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is advancing today with unusually high trading activity, breaking from a recent trend of higher daily closes since Thursday.
Lezen
15 sep 2026, 20:02 UTC
Rigel Pharmaceuticals is trading lower as the NY Empire State Manufacturing Index fell sharply, raising concerns about economic contraction in New York's manufacturing sector.
Lezen
11 sep 2026, 19:46 UTC
Rigel Pharmaceuticals is higher today, influenced by CPI data and speculation about potential Federal Reserve interest rate hikes. The stock remains near its one-month trading range.
Lezen
10 sep 2026, 23:21 UTC
Rigel Pharmaceuticals Inc is rising in after-market trading, reversing a three-session decline. No specific news was identified to explain this price action.
Lezen
8 sep 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares are lower today, continuing a decline since Friday. The stock saw notable volatility but remains above its 20-day moving average.
Lezen
1 sep 2026, 20:08 UTC
Rigel Pharmaceuticals Inc shares are higher today, reflecting strong market performance and robust momentum above the 20-day moving average. No specific news was identified.
Lezen
31 aug 2026, 20:07 UTC
Rigel Pharmaceuticals is lower today as the market reacts to comments from Warsh at the Jackson Hole Economic Symposium regarding elevated inflation and potential rate hikes.
Lezen
25 aug 2026, 20:07 UTC
Rigel Pharmaceuticals shares are advancing, supported by easing Treasury yields and lower oil prices, despite pulling back from earlier session highs.
Lezen
24 aug 2026, 19:56 UTC
Rigel Pharmaceuticals Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.
Lezen
21 aug 2026, 19:36 UTC
Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.
Lezen
20 aug 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.
Lezen
19 aug 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.
Lezen
18 aug 2026, 22:01 UTC
Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.
Lezen
17 aug 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.
Lezen
14 aug 2026, 20:06 UTC
HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.
Lezen
13 aug 2026, 19:16 UTC
Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.
Lezen
11 aug 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.
Lezen
7 aug 2026, 19:26 UTC
Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.
Lezen
6 aug 2026, 20:06 UTC
Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.
Lezen
5 aug 2026, 20:02 UTC
Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.
Lezen
4 aug 2026, 23:01 UTC
Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.
Lezen
3 aug 2026, 19:26 UTC
Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.
Lezen
31 jul 2026, 19:41 UTC
Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.
Lezen
30 jul 2026, 19:29 UTC
Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.
Lezen
29 jul 2026, 19:47 UTC
Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.
Lezen
28 jul 2026, 19:56 UTC
Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.
Lezen
27 jul 2026, 16:16 UTC
Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.
Lezen
24 jul 2026, 20:01 UTC
Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.
Lezen
22 jul 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.
Lezen
Peer Vergelijking
Prijswijziging
Rigel Pharmaceuticals Inc Prognose
Koersdoel
By TipRanks
12 Maanden Prognose
Gemiddelde 65 USD 35.05%
Hoogste 85 USD
Laagste 43 USD
Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Rigel Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.
Beoordelingsconsensus
By TipRanks
Buy
4 ratings
2
Buy
2
Hold
0
Sell
Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Rigel Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.
Sentiment
By Acuity
Nieuwssentiment
Zeer Sterk Bearish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
$